These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 19958964)

  • 1. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
    Austin PC; Mamdani MM
    Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.
    Lotfi A; Schweiger MJ; Giugliano GR; Murphy SA; Cannon CP;
    Am Heart J; 2008 May; 155(5):954-8. PubMed ID: 18440347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
    N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
    Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
    Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
    Wiviott SD; Cannon CP; Morrow DA; Ray KK; Pfeffer MA; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1411-6. PubMed ID: 16226163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
    Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
    Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
    Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
    J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP; Peng DQ; Yu BL; Huo Y;
    Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
    Ray KK; Cannon CP
    Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
    Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
    Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial.
    Leone AM; Rutella S; Giannico MB; Perfetti M; Zaccone V; Brugaletta S; Garramone B; Niccoli G; Porto I; Liuzzo G; Biasucci LM; Bellesi S; Galiuto L; Leone G; Rebuzzi AG; Crea F
    Int J Cardiol; 2008 Nov; 130(3):457-62. PubMed ID: 18667247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
    McLean DS; Ravid S; Blazing M; Gersh B; Shui A; Cannon CP
    Am Heart J; 2008 Feb; 155(2):298-302. PubMed ID: 18215600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.